Skip to main content

Letrozole / ribociclib Side Effects

Medically reviewed by Drugs.com. Last updated on Dec 5, 2023.

Applies to letrozole / ribociclib: oral tablet.

Serious side effects

Along with its needed effects, letrozole/ribociclib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking letrozole / ribociclib:

More common

Less common

Incidence not known

Other side effects

Some side effects of letrozole / ribociclib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to letrozole / ribociclib: oral tablet.

General

The most common adverse reactions and laboratory abnormalities (20% or more frequency) were decreased leukocyte count (93%), decreased neutrophil count (93%), neutropenia (75%), decreased hemoglobin count (57%), nausea (52%), decreased lymphocyte count (51%), increased ALT (46%), increased AST (44%), fatigue (37%), diarrhea (35%), alopecia (33%), leukopenia (33%), decreased platelet count (29%), vomiting (29%), constipation (25%), headache (22%), back pain (20%), and increased creatinine (20%).[Ref]

Hematologic

Very common (10% or more): Decreased leukocyte count (93%), decreased neutrophil count (93%), neutropenia (75%), decreased hemoglobin count (57%), decreased lymphocyte count (51%), leukopenia (33%), decreased platelet count (29%), anemia (18%), lymphopenia (11%)[Ref]

Gastrointestinal

Very common (10% or more): Nausea (52%), diarrhea (35%), vomiting (29%), constipation (25%), stomatitis (12%), abdominal pain (11%)[Ref]

Hepatic

Very common (10% or more): Increased ALT (46%), increased AST (44%), abnormal liver function tests (18%)

Frequency not reported: Increased blood bilirubin[Ref]

Other

Very common (10% or more): Fatigue (37%), pyrexia (13%), peripheral edema (12%)

Uncommon (0.1% to 1%): On-treatment death[Ref]

Dermatologic

Very common (10% or more): Alopecia (33%), rash (17%), pruritus (14%)[Ref]

Nervous system

Very common (10% or more): Headache (22%)

Common (1% to 10%): Syncope[Ref]

Musculoskeletal

Very common (10% or more): Arthralgia (33%), back pain (20%)

Common (1% to 10%): Fractures

Uncommon (0.1% to 1%): Osteoporosis[Ref]

Renal

Very common (10% or more): Increased creatinine (20%)[Ref]

Metabolic

Very common (10% or more): Decreased appetite (19%), decreased phosphorus (13%), decreased potassium (11%)

Frequency not reported: Hypokalemia[Ref]

Psychiatric

Very common (10% or more): Insomnia (12%)[Ref]

Respiratory

Very common (10% or more): Dyspnea (12%)[Ref]

Genitourinary

Very common (10% or more): Urinary tract infection (11%)[Ref]

Cardiovascular

Common (1% to 10%): QT interval prolongation[Ref]

References

1. Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals. PROD.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.